益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响*

doi:10.3969/j.issn.1672-5069.2021.06.025

Abstract

Abstract: Objective The purpose of this study was to investigate the effect of probiotics on intestinal barrier function of patients with liver cirrhosis (LC) complicated with spontaneous bacterial peritonitis (SBP). Methods 120 LC patients with SBP were admitted to our hospital between January 2018 and January 2020,and were randomly divided into control (n=60) and observation group (n=60). The patients in the control were given conventional supporting treatment and antimicrobial therapy, and those in thecombination were treated with enteric solution of triple viable bifidobacterium capsule for 14 days. Serum tumor necrosis factor-α (TNF-α), C - reactive protein (CRP), procalcitonin (PCT), soluble myeloid cells trigger receptor 1 (sTREM - 1), monocyte chemotactic protein 1 (MCP 1), D - lactic acid (D-Lac), diamine oxidase (DAO), lipopolysaccharide (LPS), closed tight junction protein (occludin) and small atresia with protein 1 (ZO - 1) were detected. Results At the end of 14 day treatment, the total effective rate in the observation group was 90.0%, significantly higher than 73.3% in the control group (P＜0.05); serum TNF-α, CRP, PCT, STREm-1 and McP-1 levels in the observation group were (28.1±5.0) ng/L, (14.0±2.6) mg/L, (1.1±0.2) g/L, (74.1±10.2) ng/L and (150.5±20.5) ng/L, all significantly lower than [(39.1±6.2) ng/L, (19.6±2.9) mg/L, (1.9±0.2) g/L, (114.2±12.9) ng/L and (204.1±26.5) ng/L, respectively,P<0.05] in the control; serum D-Lac, DAO, LPS, occludin and ZO-1 levels in the observation group were (4.6±0.6) mg/L, (2.7±0.4)κU/L, (0.5±0.1)κEU/ L,(0.5±0.1) and (0.4±0.1), all significantly lower than [(8.6±0.9) mg/L, (3.9±0.5) κU/L, (0.7±0.1))ΚEU/L, (0.8±0.1) and (0.8±0.2), respectively, P＜0.05] in the control. Conclusion The application of probiotic preparations has a definite clinical efficacy in the treatment of LC patients with SBP, which could effectively inhibit the secretion of inflammatory factors and improve the intestinal barrier functions.

Key words: Liver cirrhosis, Spontaneous bacterial peritonitis, Probiotics, Intestinal barrier functions, Therapy

Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis[J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.

References

[1] Hung TH, Tsai CC, Hsieh YH, et al. The effect of the first spontaneous bacterial peritonitis event on the mortality of cirrhotic patients with ascites: a nationwide population-based study in Taiwan. Gut Liver, 2016, 10(5):803-807.
[2] 谭志洁, 赵静, 刘文兴, 等. 肝硬化腹水患者并发SBP病原菌与影响因素分析. 中华医院感染学杂志, 2019, 28(19):2940-2943.
[3] 魏媛媛, 胡立芬, 李家斌. 自发性腹膜炎肠道菌群的变化研究. 中华疾病控制杂志, 2018, 22(5):532-534.
[4] Facciorusso A, Antonino M, Orsitto E, et al. Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art. Expert Rev Gastroenterol Hepatol, 2019, 13(8):751-759.
[5] Xia X, Chen J, Xia J, et al. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res, 2018, 46(9):3596-3604.
[6] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20(2):395-423.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):9-32.
[8] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010, 53(3):397-417.
[9] Assem M, Elsabaawy M, Abdelrashed M, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.Hepatol Int, 2016, 10(2):377-385.
[10] Fiore M, Di Franco S, Alfieri A, et al. Spontaneous bacterial peritonitis caused by gram-negative bacteria: an update of epidemiology and antimicrobial treatments. Expert Rev Gastroenterol Hepatol, 2019, 13(7):683-692.
[11] 陈倩, 邹健, 张渊. 肝硬化并发自发性细菌性腹膜炎的诊治进展. 中华全科医师杂志, 2004, 3(4):42-44.
[12] Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut, 2016, 65(12):2035-2044.
[13] Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients, 2019, 11(11):2642-2646.
[14] Woodhouse CA, Patel VC, Singanayagam A, et al. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther, 2018, 47(2):192-202.
[15] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol, 2020, 72(3):558-577.
[16] Hartmann P, Chu H, Duan Y, et al. Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol, 2019, 316(5):G563-G573.
[17] Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol, 2015, 21(41):11597-11608.
[18] Ahmed B, Rasul A, Tareen KZ, et al. Review- Contemporary evidence on the dynamic role of probiotics in liver diseases. Pak J Pharm Sci, 2019, 32(6):2765-2770.
[19] Ghosh G, Jesudian AB. Small intestinal bacterial overgrowth in patients with cirrhosis. J Clin Exp Hepatol, 2019, 9(2):257-267.
[20] 郑达武, 罗永香, 江款, 等. 哌拉西林/他唑巴坦联合微生态制剂治疗肝硬化合并SBP的临床疗效及对肝功能及炎性因子的影响. 中华医院感染学杂志, 2018, 28(23):3544-3548.

Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Jiang Hao, Zhang Wen, Chen Xia. Peginterferon-α and ribavirin combination in treatment of patients with chronic hepatitis C and its impact on resting energy expenditure and nutritional status [J]. Journal of Practical Hepatology, 2021, 24(6): 815-818.
[2]	Huang Feihu, Xue Jianya, Zhu Yongmei, et al. Short-term efficacy of sofosbuvir and velpatasvir in the treatment of patients with hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(6): 819-822.
[3]	Du Yunfei, Liu Jingrui, Ye Feixiang. Efficacy of N-acetylcysteine and dicyclol combination in the treatment of patients with antituberculous drugs-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(6): 847-850.
[4]	Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.
[5]	Liu Mei, Shi Yonghong, Ying Juan, et al. Prevalence of nosocomial infection and resistance of pathogens in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 863-866.
[6]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[7]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[8]	Ye Dong, Zhang Junxia, LiJie, et al. Risk factors of rebleeding in hepatitis B liver cirrhotics with esophageal varices bleeding after endoscopic variceal ligation [J]. Journal of Practical Hepatology, 2021, 24(6): 879-882.
[9]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.
[10]	Wang Jing, Bi Ning, Fang Liang, et al. Efficacy of transarterial intrahepatic transplantation of autologous bone marrow stem cells in the treatment of patients with decompensated hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 887-890.
[11]	Xue Kui, Xu Yinhai, Zhang Jian. Changes of serum thrombopoietin levels and its relationship with peripheral blood platelet counts in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 891-894.
[12]	Han Lichou, Xu Wang, Han Dan, et al. Observation of gastric mucosal lesions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 895-898.
[13]	Shu Qinghua, Zhang Nannan, Ge Yongsheng. Impact of HCV genotypes on the treatment response of recombinant human interferon α-2a in patients with chronic hepatitis C and hepatitis C liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 899-902.
[14]	Yu Shigang, Tian Jia, Wu Tie, et al. Damage control surgery in dealing with patients with traumatic liver rupture [J]. Journal of Practical Hepatology, 2021, 24(6): 915-918.
[15]	Cai Chuang, Fan Ruoying, Li Wei, et al. Impact of periampullary diverticula on surgical efficacy of ERCP in dealing with patients with choledocholithiasis [J]. Journal of Practical Hepatology, 2021, 24(6): 919-922.